Opportunity Information: Apply for RFA AR 14 015
Apply for RFA AR 14 015
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Accelerating Medicines Partnership (AMP) in Rheumatoid Arthritis and Lupus Network Leadership Center (UM2)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.846 Arthritis, Musculoskeletal and Skin Diseases Research 93.855 Allergy and Infectious Diseases Research 93.856 Microbiology and Infectious Diseases Research.
- This funding opportunity was created on Mar 21, 2014 and posted on Mar 21, 2014.
- Applicants must submit their applications by May 21, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $1,400,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $2,000,000.00 in funding.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: City or township governments Small businesses Special district governments For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Others (see text field entitled Additional Information on Eligibility for clarification) State governments Private institutions of higher education Native American tribal governments (Federally recognized) Independent school districts Public and State controlled institutions of higher education County governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity titled "Accelerating Medicines Partnership (AMP) in Rheumatoid Arthritis and Lupus Network Leadership Center (UM2)" is a National Institutes of Health (NIH) cooperative agreement focused on building and coordinating a leadership center for a major, multi-site research network. The central aim is to support the Accelerating Medicines Partnership in Rheumatoid Arthritis (RA) and Lupus by organizing a collaborative effort that can map and compare the biological pathways that drive these autoimmune diseases. The larger scientific goal is practical: by clarifying which pathways are shared across RA and lupus and which are disease-specific, the program seeks to identify and prioritize drug targets that are more likely to translate into effective therapies.
At the heart of the AMP RA and Lupus Network is a systems-level approach to understanding disease biology. Rather than relying on a narrow set of markers or single-gene hypotheses, the program emphasizes broad profiling of gene expression and cellular signaling. It specifically highlights analysis of "target tissues" from affected end organs, along with peripheral blood cells, so that investigators can connect what is happening at the site of disease damage with what can be measured in blood. This kind of design is meant to improve how researchers define disease mechanisms, stratify patients, and uncover molecular signatures that could be actionable in drug development, including targets that may not be obvious through traditional approaches.
Administratively, the opportunity is offered under Funding Opportunity Number RFA-AR-14-015 and uses a cooperative agreement mechanism, reflecting NIH's intent to remain substantially involved in the project’s direction and oversight. Cooperative agreements typically indicate that awardees will work closely with NIH program staff and likely with other AMP partners, following shared milestones, governance structures, data standards, and coordination requirements that are common in large consortium science. The activity category is Health, and the opportunity anticipates a single award, meaning one selected applicant would serve as the coordinating or leadership hub for the network rather than funding many independent, unconnected projects.
In terms of funding, the opportunity lists an estimated total funding level of $1,400,000 and an award ceiling of $2,000,000, with no cost sharing or matching requirement. While the numbers provide an overall sense of scale, the key takeaway is that the award is meant to underwrite leadership, coordination, and network-level execution rather than acting as a broad, multi-award investigator-initiated program. The CFDA numbers connected to the announcement include 93.846 (Arthritis, Musculoskeletal and Skin Diseases Research), 93.855 (Allergy and Infectious Diseases Research), and 93.856 (Microbiology and Infectious Diseases Research), signaling cross-institute relevance and the immune-mediated nature of RA and lupus research.
Eligibility is broad and includes many types of U.S. organizations and governments, such as public and private institutions of higher education, nonprofit organizations (including those with and without 501(c)(3) status), small businesses and other for-profit entities, and a wide range of governmental bodies (state, county, city/township, special district, and independent school districts). The announcement also explicitly includes additional eligible applicants such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribal Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and other designated serving institutions, along with faith-based or community-based organizations and regional organizations. Importantly, foreign components are allowed as defined by the NIH Grants Policy Statement, which can enable international collaborations when they provide unique expertise, populations, specimens, or capabilities that strengthen the network’s scientific goals.
The timeline reflects a 2014 funding cycle: it was posted and created on March 21, 2014, with an original and current closing date of May 21, 2014, and an archive date of June 21, 2014. Even though it is archived, the structure and intent remain a useful reference point for understanding how NIH and AMP-style programs organize large, target-focused consortia aimed at accelerating translational progress.
Overall, this funding opportunity is best understood as an NIH-backed effort to establish a central leadership and coordination entity for a consortium that studies RA and lupus using integrated, high-dimensional biology. By combining tissue-based and blood-based profiling of gene expression and signaling pathways, the program aims to produce a clearer, more complete map of autoimmune disease mechanisms, ultimately improving the identification of credible therapeutic targets and supporting the broader goal of accelerating treatment development for these chronic, debilitating diseases.
FAQs: Accelerating Medicines Partnership (AMP) in Rheumatoid Arthritis and Lupus Network Leadership Center (UM2)
What is the title of this grant opportunity?
The opportunity is titled "Accelerating Medicines Partnership (AMP) in Rheumatoid Arthritis and Lupus Network Leadership Center (UM2)."
Which federal agency is offering this opportunity?
This is a National Institutes of Health (NIH) funding opportunity.
What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number is RFA-AR-14-015.
What kind of award mechanism is being used?
The opportunity uses a cooperative agreement mechanism, which indicates NIH expects substantial involvement in the project’s direction and oversight.
What does it mean that this is a cooperative agreement?
Based on the information provided, a cooperative agreement suggests the awardee will work closely with NIH program staff (and likely other AMP partners) and will follow shared milestones, governance structures, data standards, and coordination requirements typical of large consortium efforts.
What is the main purpose of this award?
The award is intended to build and coordinate a leadership center for a major, multi-site research network supporting the AMP effort in Rheumatoid Arthritis (RA) and Lupus. The leadership center functions as the coordinating or leadership hub for the network.
Is this intended to fund multiple independent research projects?
No. The key intent described is to underwrite leadership, coordination, and network-level execution rather than operate as a broad, multi-award, investigator-initiated program.
How many awards are anticipated?
The opportunity anticipates a single award, meaning one selected applicant would serve as the central coordinating hub for the network.
What is the estimated total funding for the opportunity?
The estimated total funding level listed is $1,400,000.
What is the award ceiling?
The award ceiling is $2,000,000.
Is cost sharing or matching required?
No. The opportunity states there is no cost sharing or matching requirement.
What is the primary scientific focus of the network?
The network focuses on Rheumatoid Arthritis (RA) and Lupus and aims to map and compare the biological pathways driving these autoimmune diseases.
What is the larger scientific goal of comparing RA and Lupus pathways?
The goal is to clarify which pathways are shared across RA and Lupus and which are disease-specific, in order to identify and prioritize drug targets that are more likely to translate into effective therapies.
What research approach is emphasized?
A systems-level approach is emphasized, relying on broad profiling of gene expression and cellular signaling rather than focusing on a narrow set of markers or single-gene hypotheses.
What types of samples or biological materials are highlighted for analysis?
The opportunity specifically highlights analysis of target tissues from affected end organs, along with peripheral blood cells, to connect what is happening at the disease site with what can be measured in blood.
Why does the opportunity emphasize both target tissues and blood?
This design is intended to help investigators connect local disease processes in affected organs to measurable signals in blood, improving how disease mechanisms are defined, how patients may be stratified, and how actionable molecular signatures may be discovered.
How is this work expected to help drug development?
By producing clearer maps of disease mechanisms and identifying molecular signatures, the program aims to surface credible therapeutic targets, including targets that may not be obvious through traditional approaches.
What is the activity category for this opportunity?
The activity category is Health.
Which CFDA numbers are associated with this announcement?
The CFDA numbers listed are 93.846 (Arthritis, Musculoskeletal and Skin Diseases Research), 93.855 (Allergy and Infectious Diseases Research), and 93.856 (Microbiology and Infectious Diseases Research).
What do the listed CFDA numbers suggest about the program?
They indicate cross-institute relevance and emphasize the immune-mediated nature of RA and Lupus research.
Who is eligible to apply?
Eligibility is broad and includes many types of U.S. organizations and governments, including public and private institutions of higher education, nonprofit organizations (with or without 501(c)(3) status), small businesses and other for-profit entities, and a wide range of governmental bodies (state, county, city/township, special district, and independent school districts).
Are designated serving institutions included in the eligibility list?
Yes. The opportunity explicitly includes Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribal Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and other designated serving institutions.
Can faith-based or community-based organizations apply?
Yes. Faith-based or community-based organizations are explicitly included among eligible applicants.
Are regional organizations eligible?
Yes. Regional organizations are listed as eligible applicants.
Are foreign components allowed?
Yes. Foreign components are allowed as defined by the NIH Grants Policy Statement, which can support international collaboration when it contributes unique expertise, populations, specimens, or capabilities aligned with the network’s goals.
What are the key dates associated with this opportunity?
The opportunity was posted and created on March 21, 2014. The original and current closing date is May 21, 2014. The archive date is June 21, 2014.
Is this funding opportunity still open?
No. The opportunity is archived, with an archive date of June 21, 2014, and a closing date of May 21, 2014.
If it is archived, why might it still be useful to review?
Even though it is archived, it remains a useful reference for understanding how NIH and AMP-style programs structure large, target-focused consortia and how leadership and coordination functions are organized to accelerate translational progress.
What role would the selected awardee likely play in the network?
The selected awardee would serve as the network’s leadership and coordination center, supporting network-level organization and execution and working within consortium-style milestones, governance, and shared standards described in the opportunity.
Browse more opportunities from the same category: Health
Next opportunity: Accelerating Medicines Partnership (AMP) in Rheumatoid Arthritis and Lupus Network Research Sites (UH2/UH3)
Previous opportunity: NEW JERSEY FY2014 CONSERVATION INNOVATION GRANT (CIG)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AR 14 015
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AR 14 015) also looked into and applied for these:
| Funding Opportunity |
|---|
| Accelerating Medicines Partnership (AMP) in Rheumatoid Arthritis and Lupus Network Research Sites (UH2/UH3) Apply for RFA AR 14 016 Funding Number: RFA AR 14 016 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Modeling Immunity for Biodefense (U19) Apply for RFA AI 14 028 Funding Number: RFA AI 14 028 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| CDCs National Undergraduate Student Program A Public Helath Workplace Experience to Increase Student Interest in Public Health Apply for CDC RFA MN11 110104CONT14 Funding Number: CDC RFA MN11 110104CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Building Capacity and Networks to Address Emerging Infectious Diseases in the Americas Apply for CDC RFA CK13 130102CONT14 Funding Number: CDC RFA CK13 130102CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Leveraging a Recovery Act Resource to Accelerate Research on Neurodevelopment (R01) Apply for RFA MH 15 400 Funding Number: RFA MH 15 400 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Provider Education and Public Awareness about Primary Immunodeficiency Disease Apply for CDC RFA OE12 120303CONT14 Funding Number: CDC RFA OE12 120303CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Targeting Latently Infected Cells Without Reactivation (R01) Apply for RFA AI 14 021 Funding Number: RFA AI 14 021 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| National Center for HIV, Viral Hepatitis, STD and TB Prevention (NCHHSTP) Apply for CDC RFA PS13 131502CONT14 Funding Number: CDC RFA PS13 131502CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| NIAID Division of Allergy, Immunology and Transplantation Statistical and Clinical Coordinating Center (UM2) Apply for RFA AI 14 016 Funding Number: RFA AI 14 016 Agency: National Institutes of Health Category: Health Funding Amount: $16,500,000 |
| National Environmental Medicine Education and Consultation Project (NEMECP) Apply for CDC RFA TS14 1401 Funding Number: CDC RFA TS14 1401 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Reduce Hepatitis Infections by Treatment and Integrated Prevention Services (Hepatitis TIPS) among Non urban Young Persons Who Inject Drugs Apply for RFA PS 14 004 Funding Number: RFA PS 14 004 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $300,000 |
| National Diabetes Prevention Program Preventing Type 2 Diabetes Among People at High Risk Apply for CDC RFA DP12 121203CONT14 Funding Number: CDC RFA DP12 121203CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| High Impact Neuroscience Research Resource Grants (R24) Apply for RFA NS 14 006 Funding Number: RFA NS 14 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Clinical Studies of Mental Illness Not Involving Treatment Development, Efficacy, or Effectiveness Trials (Collaborative R01) Apply for PAR 14 165 Funding Number: PAR 14 165 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Service Area Competition Additional Area (SAC AA) Warrenton, GA Apply for HRSA 14 136 Funding Number: HRSA 14 136 Agency: Health Resources and Services Administration Category: Health Funding Amount: $1,185,045 |
| Biology of Manual Therapies (R21) Apply for PA 14 167 Funding Number: PA 14 167 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Biology of Manual Therapies (R01) Apply for PA 14 168 Funding Number: PA 14 168 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| The Affordable Care Act and What it Means for People with Disabilities Apply for NCD0114 Funding Number: NCD0114 Agency: National Council on Disability Category: Health Funding Amount: $135,000 |
| Fetal Alcohol Spectrum Disorders Practice and Implementation Centers Apply for CDC RFA DD14 1402 Funding Number: CDC RFA DD14 1402 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $275,000 |
| Improving Fetal Alcohol Spectrum Disorders Prevention and Practice through National Partnerships Apply for CDC RFA DD14 1403 Funding Number: CDC RFA DD14 1403 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AR 14 015", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.